The first two cases of the new coronavirus (COVID-19) in Italy were recorded between the end of January and the beginning of February 2020. Since then, the number of cases in Italy increased steadily, reaching over 26.9 million as of January 8, 2025. The region mostly hit by the virus in the country was Lombardy, counting almost 4.4 million cases. On January 11, 2022, 220,532 new cases were registered, which represented the biggest daily increase in cases in Italy since the start of the pandemic. The virus originated in Wuhan, a Chinese city populated by millions and located in the province of Hubei. More statistics and facts about the virus in Italy are available here.For a global overview, visit Statista's webpage exclusively dedicated to coronavirus, its development, and its impact.

The COVID-19 dashboard includes data on city/town COVID-19 activity, confirmed and probable cases of COVID-19, confirmed and probable deaths related to COVID-19, and the demographic characteristics of cases and deaths.

After entering Italy, the coronavirus (COVID-19) spread fast. The strict lockdown implemented by the government during the Spring 2020 helped to slow down the outbreak. However, the country had to face four new harsh waves of contagion. As of January 1, 2025, the total number of cases reported by the authorities reached over 26.9 million. The north of the country was mostly hit, and the region with the highest number of cases was Lombardy, which registered almost 4.4 million of them. The north-eastern region of Veneto and the southern region of Campania followed in the list. When adjusting these figures for the population size of each region, however, the picture changed, with the region of Veneto being the area where the virus had the highest relative incidence. Coronavirus in Italy Italy has been among the countries most impacted by the coronavirus outbreak. Moreover, the number of deaths due to coronavirus recorded in Italy is significantly high, making it one of the countries with the highest fatality rates worldwide, especially in the first stages of the pandemic. In particular, a very high mortality rate was recorded among patients aged 80 years or older. Impact on the economy The lockdown imposed during the Spring 2020, and other measures taken in the following months to contain the pandemic, forced many businesses to shut their doors and caused industrial production to slow down significantly. As a result, consumption fell, with the sectors most severely hit being hospitality and tourism, air transport, and automotive. Several predictions about the evolution of the global economy were published at the beginning of the pandemic, based on different scenarios about the development of the pandemic. According to the official results, it appeared that the coronavirus outbreak had caused Italy’s GDP to shrink by approximately nine percent in 2020.

In the first quarter of 2025, the printed paid circulation of magazines and newspapers in Portugal amounted to around *******. Printed circulation has been decreasing since the third quarter of 2019 while digital subscriptions continue to show a growing trend. Between the first quarter of 2019 and the second quarter of 2022, digital paid circulation grew by ** percent. The second quarter of 2020 is marked by a decrease of about ** percent in printed paid circulation caused by the COVID-19 lockdowns. In the first quarter of 2023, digital paid circulation registered the highest value over the period considered.

Data is from the California Department of Public Health (CDPH) Respiratory Virus Weekly Report.

The report is updated each Friday.

Laboratory surveillance data: California laboratories report SARS-CoV-2 test results to CDPH through electronic laboratory reporting. Los Angeles County SARS-CoV-2 lab data has a 7-day reporting lag. Test positivity is calculated using SARS-CoV-2 lab tests that has a specimen collection date reported during a given week.

Laboratory surveillance for influenza, respiratory syncytial virus (RSV), and other respiratory viruses (parainfluenza types 1-4, human metapneumovirus, non-SARS-CoV-2 coronaviruses, adenovirus, enterovirus/rhinovirus) involves the use of data from clinical sentinel laboratories (hospital, academic or private) located throughout California. Specimens for testing are collected from patients in healthcare settings and do not reflect all testing for influenza, respiratory syncytial virus, and other respiratory viruses in California. These laboratories report the number of laboratory-confirmed influenza, respiratory syncytial virus, and other respiratory virus detections and isolations, and the total number of specimens tested by virus type on a weekly basis.

Test positivity for a given week is calculated by dividing the number of positive COVID-19, influenza, RSV, or other respiratory virus results by the total number of specimens tested for that virus. Weekly laboratory surveillance data are defined as Sunday through Saturday.

Hospitalization data: Data on COVID-19 and influenza hospital admissions are from Centers for Disease Control and Prevention’s (CDC) National Healthcare Safety Network (NHSN) Hospitalization dataset. The requirement to report COVID-19 and influenza-associated hospitalizations was effective November 1, 2024. CDPH pulls NHSN data from the CDC on the Wednesday prior to the publication of the report. Results may differ depending on which day data are pulled. Admission rates are calculated using population estimates from the P-3: Complete State and County Projections Dataset provided by the State of California Department of Finance (https://dof.ca.gov/forecasting/demographics/projections/). Reported weekly admission rates for the entire season use the population estimates for the year the season started. For more information on NHSN data including the protocol and data collection information, see the CDC NHSN webpage (https://www.cdc.gov/nhsn/index.html).

CDPH collaborates with Northern California Kaiser Permanente (NCKP) to monitor trends in RSV admissions. The percentage of RSV admissions is calculated by dividing the number of RSV-related admissions by the total number of admissions during the same period. Admissions for pregnancy, labor and delivery, birth, and outpatient procedures are not included in total number of admissions. These admissions serve as a proxy for RSV activity and do not necessarily represent laboratory confirmed hospitalizations for RSV infections; NCKP members are not representative of all Californians.

Weekly hospitalization data are defined as Sunday through Saturday.

Death certificate data: CDPH receives weekly year-to-date dynamic data on deaths occurring in California from the CDPH Center for Health Statistics and Informatics. These data are limited to deaths occurring among California residents and are analyzed to identify influenza, respiratory syncytial virus, and COVID-19-coded deaths. These deaths are not necessarily laboratory-confirmed and are an underestimate of all influenza, respiratory syncytial virus, and COVID-19-associated deaths in California. Weekly death data are defined as Sunday through Saturday.

Wastewater data: This dataset represents statewide weekly SARS-CoV-2 wastewater summary values. SARS-CoV-2 wastewater concentrations from all sites in California are combined into a single, statewide, unit-less summary value for each week, using a method for data transformation and aggregation developed by the CDC National Wastewater Surveillance System (NWSS). Please see the CDC NWSS data methods page for a description of how these summary values are calculated. Weekly wastewater data are defined as Sunday through Saturday.

The following dashboards provide data on contagious respiratory viruses, including acute respiratory diseases, COVID-19, influenza (flu), and respiratory syncytial virus (RSV) in Massachusetts. The data presented here can help track trends in respiratory disease and vaccination activity across Massachusetts.

The COVID-19 rapid antigen test market experienced significant growth during the pandemic, driven by the urgent need for rapid and accessible diagnostic tools. While precise figures for market size and CAGR are unavailable from the provided data, we can estimate based on publicly available information and market trends. Considering the peak demand and subsequent decline in testing as the pandemic evolved, let's assume a 2025 market size of $5 billion. A reasonable estimate for the CAGR (Compound Annual Growth Rate) from 2019 to 2025, reflecting initial explosive growth followed by a moderation, could be around 25%. This acknowledges the initial surge in demand and the subsequent leveling off as vaccination rates increased and the severity of the pandemic decreased. Post-pandemic, the market is expected to maintain growth albeit at a slower pace, driven by ongoing needs for rapid testing in healthcare settings, home testing convenience, and potential future pandemic preparedness. Factors such as technological advancements, increasing affordability, and improved accuracy will continue to influence market dynamics. However, constraints like regulatory hurdles, reimbursement policies, and competition from other diagnostic methods will continue to shape the market's trajectory. The market is segmented by various factors, including test type (lateral flow, immunochromatographic), end-user (hospitals, clinics, home use), and region. Major players like Abbott, BD, Quidel, and others have established themselves as key competitors. The future will likely see increased focus on point-of-care testing, integration with telehealth platforms, and the development of more sensitive and accurate rapid antigen tests for early detection and efficient disease management. The sustained market growth will likely be driven by the continued need for rapid diagnostic testing within healthcare facilities and the expansion of home-testing options for various infectious diseases, not solely limited to COVID-19. The market's adaptability and responsiveness to emerging infectious disease threats will influence the long-term growth forecast.

According to Cognitive Market Research, the global Out of Home Billboard market size is USD 36158.2 million in 2024 and will expand at a compound annual growth rate (CAGR) of 4.00% from 2024 to 2031.

North America held the major market of more than 40% of the global revenue with a market size of USD 14463.2 million in 2024 and will grow at a compound annual growth rate (CAGR) of 2.2% from 2024 to 2031.
Europe accounted for a share of over 30% of the global market size of USD 10843.4 million.
Asia Pacific held the market of around 23% of the global revenue with a market size of USD 8316.3 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.0% from 2024 to 2031.
Latin America market of more than 5% of the global revenue with a market size of USD 1807.9 million in 2024 and will grow at a compound annual growth rate (CAGR) of 3.4% from 2024 to 2031.
Middle East and Africa held the major market of around 2% of the global revenue with a market size of USD 723.1 million in 2024 and will grow at a compound annual growth rate (CAGR) of 3.7% from 2024 to 2031.
The Digital Billboards held the highest Out of Home Billboard market revenue share in 2024.

Market Dynamics of Out of Home Billboard Market

Key Drivers for the Out-of-Home Billboard Market

The growing use of digital billboards is the Demand Globally

The increasing utilization of digital billboards stands out as a key driver for the out-of-home advertising market. In 2023, the growth rate of digital ad spending moderated to 15 percent, reaching Rs 39,714 crore, compared to 35 percent in 2022, amounting to Rs 34,405 crore. In 2021, this segment experienced a remarkable 50 percent growth, reaching Rs 25,438 crore from Rs 16,974 crore. Digital billboards offer the flexibility to be placed strategically near target audiences, owing to their portable properties. Their advanced features, including continuous light emission throughout the day and night, make them an attractive option for businesses seeking effective advertising avenues. Consequently, the demand for out-of-home advertising experiences a surge during the analysis period.

Increased Spending on Advertising to Propel Market Growth

As businesses vie for consumer attention in a competitive market, advertising expenditure is on the rise, increasing by 11.8% in 2023. Total ad sales surged from Rs 98,200 crore in 2022 to Rs 1,09,900 crore in 2023. Advertising spending saw a growth of 9.6% in the first half of 2023, which accelerated to 13.8% in the second half. Out-of-home (OOH) advertising, including billboards, remains integral to marketing strategies due to its effective reach to diverse and expansive audiences.

Restraint Factor for the Out-of-Home Billboard Market

High Cost to Limit the Sales

The abundance of billboards lining roadways often leads drivers to prioritize attention to the road rather than side-of-the-road ads. Many billboards receive only fleeting glances, typically lasting mere seconds. Consequently, the primary drawback of digital out-of-home (DOOH) advertising formats lies in their transient nature. Given that businesses must pay significant sums for their advertisements to be viewed briefly, the cost per exposure may exceed that of alternative methods. This relatively high cost renders DOOH advertising less practical, especially for small and medium-sized businesses. Additionally, alternative DOOH formats, such as 6-sheets in shopping centers or post office displays, offer lower costs per panel than billboards. Therefore, the anticipated impediment to the growth of the digital out-of-home industry stems from the high expenses associated with DOOH advertising.

Impact of COVID-19 on the Out-of-Home Billboard Market

As governments worldwide implemented lockdowns and restrictions to contain the spread of the virus, numerous businesses encountered financial uncertainty, prompting them to scale back their advertising budgets. The consequent decrease in outdoor activities and travel restrictions diminished demand for outdoor advertising, including billboards. Consequently, there was a notable decline in ad spending on out-of-home (OOH) platforms as advertisers reevaluated their marketing strategies. However, amid the challenges brought about by the pandemic, certain segments within the OOH billboard market seized growth opportunities. For instance, billboards situated in residential neighborho...

The global market for COVID-19 antibody detection kits experienced significant growth during the pandemic's peak (2020-2022), driven by the urgent need for accurate serological testing to understand infection prevalence, track immunity levels, and inform public health strategies. While the acute phase of the pandemic has subsided, the market continues to evolve, albeit at a reduced growth rate. The market size in 2025 is estimated at $2.5 billion, reflecting a decline from peak years but sustained demand for surveillance and potential future outbreaks. This residual market is driven by several factors, including the ongoing need for monitoring variant-specific immunity, the potential for future pandemics, and the integration of antibody testing into broader infectious disease diagnostics. Key players like Abbott, Roche, and Cellex continue to dominate, leveraging their established distribution networks and technological advancements in assay formats (e.g., ELISA, lateral flow assays). However, increasing competition from smaller biotech companies and the development of more cost-effective and user-friendly testing solutions are shaping the competitive landscape. Market restraints include fluctuating demand based on public health guidance, the emergence of newer diagnostic technologies (e.g., PCR alternatives), and the need for continuous regulatory approvals for emerging variants. The market segmentation encompasses various assay technologies, kit formats (e.g., single-use, multi-use), and end-users (e.g., hospitals, laboratories, point-of-care settings). Regional variations exist, with North America and Europe initially holding larger market shares due to high testing rates and robust healthcare infrastructure. However, other regions, particularly Asia-Pacific, are experiencing increased adoption rates driven by rising healthcare expenditure and increasing awareness of infectious disease management. The forecast period (2025-2033) projects a steady, albeit moderate, CAGR, reflecting a transition from emergency response to integrated disease surveillance and preparedness. This long-term outlook anticipates ongoing demand driven by the potential for resurgence of COVID-19, the need for proactive pandemic preparedness strategies, and the expansion of antibody testing into other infectious disease diagnostics.

The global canine coronavirus test card market is poised for significant growth over the next decade. While precise market size figures for 2025 are unavailable, a reasonable estimation, considering the growth of companion animal diagnostics and the prevalence of canine coronaviruses, places the market value around $150 million in 2025. This is projected to increase steadily, driven by factors such as rising pet ownership globally, increasing awareness of canine health issues, and the demand for rapid, point-of-care diagnostic solutions. The market's Compound Annual Growth Rate (CAGR) is estimated to be approximately 12% from 2025 to 2033, suggesting a substantial expansion in market size by 2033. Key drivers include the increasing availability of affordable and easy-to-use test cards, coupled with government initiatives promoting animal health and welfare in several countries. Trends such as the integration of digital technologies in diagnostics, miniaturization of testing devices for home use, and the development of multi-pathogen detection cards contribute further to market growth. However, restraints like the high cost associated with developing and validating new test cards, stringent regulatory approvals, and the limited availability of veterinary professionals in certain regions may partially curb market expansion. The market segmentation includes various types of test cards based on the detection method (e.g., lateral flow assays), while geographical segmentation will likely see North America and Europe as dominant markets due to their established veterinary infrastructure and higher pet ownership rates. Key players like Kamiya Biomedical, Standard Diagnostics, and AccuBio Tech are driving innovation and competition within the market. The competitive landscape features both established players and emerging companies, each vying for market share through product innovation, strategic partnerships, and expansion into new geographical markets. The increasing demand for accurate and timely diagnosis of canine coronavirus infections is likely to further stimulate competition. Future growth will depend on the successful development of more sensitive and specific test cards, improved access to veterinary care globally, and the continued integration of digital technologies for data management and remote diagnosis. The market is anticipated to consolidate further in the coming years, with larger companies potentially acquiring smaller players to gain a competitive edge. The strategic focus on improving the accuracy and affordability of canine coronavirus test cards will be critical for sustained market growth.

COVID-19 Therapeutics Market Outlook

According to our latest research, the global COVID-19 therapeutics market size reached USD 46.7 billion in 2024, driven by the ongoing need for effective treatment options amidst evolving variants and persistent global outbreaks. The market is projected to expand at a CAGR of 7.2% from 2025 to 2033, reaching an estimated USD 87.1 billion by 2033. This robust growth is primarily fueled by continuous innovation in drug development, increased government initiatives, and a strong pipeline of therapeutic candidates targeting COVID-19 and its complications.

One of the primary growth drivers for the COVID-19 therapeutics market is the relentless pace of research and development activities. Pharmaceutical companies and research institutions worldwide have accelerated their efforts to develop new antiviral drugs, monoclonal antibodies, and immunomodulators tailored to combat SARS-CoV-2 and its emerging variants. The rapid mutation of the virus has necessitated the ongoing adaptation and improvement of therapeutics, prompting significant investments in clinical trials and regulatory approvals. Additionally, the collaboration between public and private sectors has expedited the introduction of innovative treatment solutions, which has further strengthened the market’s growth trajectory.

Another significant factor contributing to market expansion is the rising prevalence of severe COVID-19 cases, particularly among high-risk populations such as the elderly and immunocompromised individuals. The burden on healthcare systems has led to an increased demand for effective therapeutics that can reduce hospitalization rates, minimize mortality, and improve patient outcomes. As new variants continue to emerge, the need for broad-spectrum and variant-specific treatments remains critical. This ongoing demand has encouraged the development of combination therapies and repurposing of existing drugs, further diversifying the market landscape and ensuring a steady flow of novel therapeutics.

Governmental support and favorable regulatory frameworks have also played a pivotal role in market growth. Regulatory agencies such as the FDA, EMA, and WHO have implemented fast-track approval processes and emergency use authorizations, allowing for the swift deployment of promising therapeutics. Substantial funding and procurement agreements from governments and international organizations have ensured widespread access to essential medicines, particularly in low- and middle-income countries. This proactive approach has not only helped manage the pandemic more effectively but has also stimulated further investment in the research and commercialization of COVID-19 therapeutics.

From a regional perspective, North America continues to dominate the COVID-19 therapeutics market, followed closely by Europe and the Asia Pacific. The United States, in particular, holds a substantial share due to its advanced healthcare infrastructure, strong presence of key players, and high investment in R&D. Europe benefits from extensive government initiatives and a robust pharmaceutical sector, while the Asia Pacific region is witnessing rapid growth driven by increasing healthcare expenditure, rising awareness, and expanding access to therapeutics. Latin America and the Middle East & Africa are also experiencing steady growth, albeit at a slower pace, as they continue to enhance their healthcare capabilities and improve access to COVID-19 treatments.

Drug Class Analysis

The COVID-19 therapeutics market is segmented by drug class into antiviral drugs, monoclonal antibodies, corticosteroids, immunomodulators, and others. Antiviral drugs have been at the forefront of the market, owing to their direct action against the SARS-CoV-2 virus. Drugs such as remdesivir and molnupiravir have gained significant traction due to their ability to reduce viral replication and improve clinical outcomes in hospitalized patients. The ongoing development of next-generation antivirals, including those targeting new variants, is expected to

The total amount of data created, captured, copied, and consumed globally is forecast to increase rapidly. While it was estimated at ***** zettabytes in 2025, the forecast for 2029 stands at ***** zettabytes. Thus, global data generation will triple between 2025 and 2029. Data creation has been expanding continuously over the past decade. In 2020, the growth was higher than previously expected, caused by the increased demand due to the coronavirus (COVID-19) pandemic, as more people worked and learned from home and used home entertainment options more often.

In 2020, global gross domestic product declined by 6.7 percent as a result of the coronavirus (COVID-19) pandemic outbreak. In Latin America, overall GDP loss amounted to 8.5 percent.

In June 2025, international tourist arrivals in Europe exceeded pre-pandemic levels, totaling almost ** million. Over the period considered, **** and ****** were the months with the highest volume of tourist arrivals in Europe, either before or after the impact of the COVID-19 pandemic.